Imugene Ltd (ASX:IMU, OTC:IUGNF)'s Leslie Chong speaks to Proactive after announcing a phase one trial of the company's oncolytic virotherapy candidate would proceed to the second dose cohort at City of Hope, a world-renowned independent cancer research and treatment centre near Los Angeles. The current trial design will involve a dose escalation of Imugene's CHECKvacc drug candidate, followed by an expansion to 12 patients at the final dose.
Imugene talks dose escalation for CHECKvacc's City of Hope trial
